



Matthew M. Holub

Associate

matthew.holub@kattenlaw.com

Chicago

p +1.312.902.5326

Practices

FOCUS: Intellectual
Property Litigation

Patents

Intellectual Property
Patent Litigation

Pharmaceutical and
Life Sciences
Litigation

Industries

Pharmaceutical and
Life Sciences

Recognition

Super Lawyers Rising
Stars, Illinois, 2018

Education

JD, University of Illinois
College of Law,
magna cum laude

AB, Biological
Sciences,
specialization in
Neuroscience, The
University of
Chicago, with general
honors

Bar Admissions

Illinois

Matthew M. Holub concentrates his practice on resolving intellectual property disputes, including complex patent litigation involving the Hatch-Waxman Act and Abbreviated New Drug Applications. Matt also applies his strong foundation in the pharmaceutical industry to various complex litigation matters, including both antitrust and contractual claims.

Matt is well versed in all stages of trial and appellate practice, and has extensive experience with pleadings, electronic discovery, motion practice, trial, appellate briefing and oral argument. His awareness that clients desire to quickly reach beneficial resolutions has made him an integral part of settlement teams that have successfully resolved multimillion-dollar litigations.

Prior to practicing law, Matt worked for several years in the pharmaceutical industry, concentrating on brand identity and regulatory compliance of promotional activity. He leverages this experience to focus on his clients' business objectives in complex pharmaceutical litigation, often working closely with leading industry experts.

Matt's enthusiasm extends to all of his clients. His strong belief in client advocacy is shown through his pro bono work, which focuses on immigration law and includes several victories in which Matt successfully secured asylum for refugees fleeing persecution in their homelands.

Advisories

- US Supreme Court Adds to District Court's Ability to Award Enhanced Patent Damages (June 15, 2016)
- Comments Sought by December 19th on the FDA's Proposed Criteria for "First Generic" Applications (November 19, 2014)
- Supreme Court Rules Patent Claims Ineligible as Abstract Ideas, Affirming Federal Circuit in *Alice Corp Pty. Ltd. v. CLS Bank Int'l* (June 19, 2014)



Court Admissions

US District Court,
Northern District of
Illinois

US Court of Appeals,
Federal Circuit

US Court of Appeals,
Third Circuit

